Mitesh Borad, MD
Enriched profileProfessor of Medicine, Mayo Clinic College of Medicine and Science · Mayo Clinic
Mitesh Borad is Professor of Medicine, Mayo Clinic College of Medicine and Science at Mayo Clinic. OpenAlex indexes 764 publications with 60,996 citations (h-index 84); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Mitesh Borad, MD, is Professor of Medicine, Mayo Clinic College of Medicine and Science. The public record shows 764 publications with 60,996 citations (h-index 84), centered on Hepatobiliary Cancer, Pancreatic Cancer, Kidney Cancer / RCC. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 17 companies, 3 NIH-funded awards (2014–2024).
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Hepatobiliary Cancer
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 30 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Sponsor: Tango Therapeutics, Inc.
- Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Sponsor: Tango Therapeutics, Inc.
Industry payments
Updated 27 Aug 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Tempus AI, IncProgram year20252 payments
- Aveo Pharmaceuticals, Inc.Program year20251 payment
- Ipsen Biopharmaceuticals, IncProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
70.2%CD38-directed Cytolytic Antibody22.2%Daratumumab100%Part B, office-administered≥46 patientsMicrotubule Inhibitor16.7%Paclitaxel59%Paclitaxel protein-bound particles41%Part B, office-administered≥22 patientsMetabolism & gastrointestinal
20.2%Other antiemetics16.3%Fosaprepitant100%Part B, office-administered≥40 patientsSerotonin-3 Receptor Antagonist3.7%Ondansetron hydrochloride52%Palonosetron hcl47%Ondansetron Hcl1%Part D + Part B≥70 patientsMusculoskeletal
4.2%RANK Ligand Inhibitor4.1%Denosumab100%Part B, office-administered≥20 patientsBisphosphonate0.1%Zoledronic acid100%Part B, office-administered≥11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2014–2024 per NIH RePORTER. The latest:
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers.
JCO precision oncology
Article2026 - ErbB Receptor Feedback Inhibitor 1 Mutation in Biliary Tract Cancers: Turning Resistance Into Response.
JCO precision oncology
Article2026
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/scientific-contributions/Mitesh-J-Borad-15565518
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
newsnetwork.mayoclinic.org/discussion/targeting-bile-duct-cancer-meet-mitesh-borad-m-d
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →newsnetwork.mayoclinic.org ↗ - X / Twitter
X/Twitter: @MiteshBorad
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →twitter.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- M.D.
Rutgers New Jersey Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗ - Board certification
Medical Oncology, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →data.the-asci.org ↗
- Principal investigator
SWOG S1815 phase III trial (gemcitabine/cisplatin +/- nab-paclitaxel in advanced biliary tract cancer)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopubs.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →alumniassociation.mayo.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →data.the-asci.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗
Secondary affiliations
appointments beyond the home institution- Program Leader
Gene and Virus Therapy Program, Mayo Clinic Comprehensive Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗ - Founding Director
Precision Cancer Therapeutics Program, Mayo Clinic Center for Individualized Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗ - Medical & Scientific Advisor
Fibrolamellar Cancer Foundation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →fibrofoundation.org ↗
Media & interviews
press, podcasts and appearances- ASCO Post video roundtable
"Metastatic Cholangiocarcinoma" / NCCN 2023 annual conference video on hepatobiliary cancer management updates
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- "Cholangio Heroes" YouTube series
Episode 20 featuring Mitesh Borad
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →m.youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
S Rajkumar, MD
Mayo Clinic
Bradley Boeve, MD
Mayo Clinic
Rick Nishimura, MD
Mayo Clinic
Victor Montori, MD
Mayo Clinic